
Immuron (NASDAQ: IMRN)
Immuron Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Immuron Company Info
Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment is involved in research and development projects performed in Australia, Israel, and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.